Seattle Genetics ’ bladder drug gets breakthrough therapy designation
Seattle Genetics ’ cancer-killing bladder drug, Padcev, has received breakthrough therapy designation from the Federal Drug Administration, the company announced Wednesday.
The drug — made by the Bothell-based biotech in partnership with Japanese drug maker Astellas Pharma, which has a Seattle office — gained accelerated approval in December, three months ahead of schedule.
Seattle Genetics, which is the largest biotech in the Seattle area based on employee count from 2018, recorded $916.7…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Megan Campbell Source Type: news
More News: Biotechnology | Bladder Cancer | Cancer | Cancer & Oncology | Genetics | Health Management | Japan Health | Partnerships | Pharmaceuticals